Fig. 1

CRAMP is reduced in cardiac ischemia/reperfusion (I/R) injury and prevents cardiomyocyte apoptosis. a The level of the mCRAMP peptide was measured by ELISA in the infarct, border, and remote zones of mouse I/R hearts compared to a sham group (n = 5). b The level of the mCRAMP peptide was measured by ELISA in the serum from I/R mice compared to a sham group (n = 5). c qRT-PCRs were performed to measure specific genes expressed in isolated neonatal mouse cardiac myocytes (NMCMs) and fibroblasts (NMCFs) (n = 6). d The level of the mCRAMP peptide was measured by ELISA in NMCMs and NMCFs (n = 9). e The level of the mCRAMP peptide was measured by ELISA in NMCMs treated with oxygen glucose deprivation/reperfusion (OGDR) (n = 9). f, g The ratio of apoptosis after rCRAMP stimulation in OGDR-treated neonatal rat cardiomyocytes (NRCMs) as determined by TUNEL staining (f, n = 4) and Western blot (g, n = 6). Immunofluorescent staining for α-actinin was used to label cardiomyocytes. h The level of rCRAMP mRNA in NRCMs after transfection with siRNAs targeting rCRAMP (n = 3). i, j The ratio of apoptosis after transfection with rCRAMP siRNA in OGDR-treated NRCMs as determined by TUNEL staining (i, n = 4) and Western blot (j, n = 6). Immunofluorescent staining for α-actinin was used to label cardiomyocytes. Scale bar = 100 μm (f, i). Data were expressed as mean ± SD. *P < 0.05; **P < 0.01; ***P < 0.001